This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-17 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

David Evans, Ph.D.
Chief Scientific Officer at Sirnaomics


Dr. Evans obtained his BSc and PhD from Imperial College, London. Over the last 3 decades he has been responsible for building and leading scientific research teams focused on target validation and drug discovery in Oncology and other indications. David has more than 18 years’ experience in the RNAi field – building genome scale screening capabilities for target identification at TGEN and Dharmacon prior to cofounding Sirnaomics to focus on developing siRNA as a therapeutic. David previously worked in the Boston area at Millennium Pharmaceuticals and Serono Pharmaceuticals.

Agenda Sessions

  • Chairman’s Remarks

  • Novel Dual Targeting siRNA Therapeutic Offers Innovative Solution for Derm-Oncology Treatment